O130 Transarterial chemoembolization in rectal cancer: a systematic review

Abstract Background Locally advanced rectal cancer (LARC) is typically treated with neoadjuvant chemoradiotherapy. Response can be unpredictable, 8-20% of patients achieving complete pathological response, whilst 20-30% have no response or progression. Transarterial chemoembolisation (TACE) established as a non-surgical option to treat colorectal liver metastases by delivering chemotherapy and an embolic agent via its primary arterial supply. This allows for reduction in systemic toxicity higher doses tumours. There been trials TACE LARC, but role therapeutic modality still unknown. Therefore, this review aims assess existing evidence LARC whether it warrants further investigation treatment. Methods A systematic literature search was performed according Preferred Reporting Items Systematic Reviews Meta-Analyses. Databases searched included PubMed, Scopus Web Science. Risk bias assessed using the Newcastle-Ottawa scale. The outcomes objective rate, complications, recurrence, disease-free overall survival. Results Five reports were considered inclusion. Minimal complications adverse events noted. Improved rates noted four out five studies when compared regimes. One study showed reduced risk distant recurrence. Significant heterogeneity all studies. Conclusion safe modality, superiority over conventional treatment has yet demonstrated. Current inadequate quality preclinical clinical settings.